Jonathan Violin - Mar 1, 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: Chief Executive Officer, Director
Signature: /s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin
Stock symbol: VRDN
Transactions as of: Mar 1, 2022
Transactions value $: -$529,491
Form type: 4
Date filed: 3/3/2022, 03:48 PM
Previous filing: Feb 3, 2022
Next filing: Apr 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRDN	Common Stock	Sale	-$337K	-18.9K	-3.14%	$17.82	582K	Mar 1, 2022	Direct	F1
transaction	VRDN	Common Stock	Sale	-$193K	-11.1K	-1.91%	$17.36	571K	Mar 2, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.62 to $18.30. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.05 to $18.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Content

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.62 to $18.30. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.05 to $18.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.